HIV infection<unk>  is indicated in combination with other antiretroviral agents for the prevention and treatment of HIV-1 infection. HBV infection<unk>  exhibits clinical activity against the hepatitis B virus (HBV), but is not approved by the U.S. Food and Drug Administration (FDA) for the treatment of HBV infection. Among individuals with chronic HBV infection,<unk>  treatment results in significant histologic, virologic, and biochemical improvement. The safety profile of<unk>  during treatment is similar to that of a placebo.<unk> , like all other FDA approved drugs, cures neither HIV nor HBV infection. In a study involving individuals with HBV infection, symptoms of infection returned in 23% of<unk> -treated individuals who were taken off therapy. In studies involving individuals with chronic HIV infection, viral replication also resumes when study subjects are taken off therapy. As with drugs used to treat HIV infection, drugs used to treat HBV infection may have to be used in combination to prevent the evolution of drug resistant strains. The effectiveness of<unk>  in combination with other anti-HBV drugs has not been established.
Emtricitabine
Letermovir
Umifenovir
Valaciclovir
Saquinavir
Balapiravir
Entecavir
Rovafovir etalafenamide